In stage IB non-small cell lung cancer (NSCLC), prognostic factor is not well known and administration of adjuvant treatment is controversial. The C-MET is known to be associated with the pathogenesis and progression of NSCLC. Our purpose was to evaluate the impact of clinicopathological characteristics and C-MET on recurrence free survival (RFS) and cancer-specific survival (CSS) in patients with stage IB NSCLC, undergoing surgical resection.
From 2005 to 2013, 115 patients who underwent complete resection with pathological stage IB were enrolled. We retrospectively reviewed clinicopathological data and performed immunohistochemistry with anti-MET monoclonal antibody in tissue microarrays. RFS and CSS were evaluated in patients depending on clinicopathological factors and C-MET status.
The median age of 115 patients was 65 years (range: 32–82 years). The patients comprised of 78 men (68%) and 37 women (31%). The histological types were adenocarcinoma (n = 77), squamous cell carcinoma (n = 32), others (n = 6). Thirty four patients relapsed and twenty four died of cancer progression. On the univariate analysis, lymphovascular invasion (LVI) (P = .003) and C-MET overexpression (P = .014) were significantly associated with decreased RFS. Meanwhile, smoking (P = .029) and LVI (P = .040) were correlate with shortened CSS. C-MET overexpression (P = .130) were not associated with CSS. However, in larger tumor than median size (>3.5cm), C-MET overexpression (P = .039) had a relation with reduced CSS. In multivariate analysis, LVI (RFS: P = .017) and C-MET (RFS: P = 0.040) were negative independent prognostic factor for RFS, but not significant for CSS. Subgroup assessments according to LVI and C-MET co-positivity were performed with univariate and multivariate analyses. Co-presence of LVI and C-MET overexpression was a significant negative prognostic factor for CSS (P = .023) as well as RFS (P = .002) in resected stage IB NSCLC.
Our data indicates that stage IB NSCLC patients with LVI and C-MET overexpression showed poor survival outcome and adjuvant chemotherapy should be strongly recommended for these patients, especially with co-presence of LVI and C-MET overexpression.
Clinical trial identification
All authors have declared no conflicts of interest.